[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Laborie Medical Technologies Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100541933","nxt-post-market-clinical-follow-up-100541933",false,"NCT06336304","NXT Post-Market Clinical Follow-up","NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation","Inclusion Criteria:\n\n* Patients medically indicated for urodynamic study\n* Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n\nExclusion Criteria:\n\n* Patients or legally authorized representative with cognitive or psychiatric condition that interferes with or precludes direct and accurate communication regarding the study, giving informed consent or ability to complete the patient questionnaire\n* Patients with confirmed active bladder infections (not including patients with asymptotic bacteria)\n* Pregnant women\n* Patients with recent (less than 2 weeks) pelvic floor surgery\n* Requires use of suprapubic catheter","ALL",{"count":18,"type":19},180,"ESTIMATED","OBSERVATIONAL","NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations",[23,24,25,26,27],"Urinary Incontinence","Urinary Obstruction","Urinary Bladder, Overactive","Urinary Bladder, Neurogenic","Urinary Incontinence, Urge","RECRUITING","2026-05-13",{"date":31,"type":32},"2026-05-15","ACTUAL",{"date":34,"type":32},"2024-06-18",{"date":36,"type":19},"2027-03",{"name":38,"class":39},"Laborie Medical Technologies Inc.","INDUSTRY",5,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100585703","e-sense-normal-values-of-urodynamic-pressures-using-e-sense-catheters-100585703","NCT06905808","e-Sense® Normal Values of Urodynamic Pressures Using e-Sense® Catheters","ESNS-01","Inclusion Criteria:\n\n* Subjects medically indicated for Urodynamic procedure between ages 20-35 or \\> 50 years old (equally split male and female)\n* Due to aging and giving birth significantly affecting the urethra:\n* Female subjects 20-35 should be nulliparous.\n* Female subjects \\> 50 years old should have given birth to at least one child vaginally. Further caesarian births would not mean exclusion from the study.\n* Subjects with range of BMI values\n* Subject provides written authorization and\u002For consent per institution or geographical requirements\n\nExclusion Criteria:\n\n* Subjects with cognitive or psychiatric conditions that interfere with or precludes direct and accurate communication regarding the study, giving informed consent\n* Any anal \u002F rectal symptoms and\u002For surgery\n* Pregnant women\n* Subjects with active untreated bladder infections (not including patients with asymptomatic bacteruria)\n* Subjects having greater than 300 mL post void residual on the clinic visit uroflowmetry test","20 Years",{"count":50,"type":19},40,"In this post-market observational study, subjects referred to urodynamic testing will be approached to enroll in a clinical study to define the normal range of pressure values utilizing e-Sense® catheters. Urodynamic test results using the study devices will be provided back to the study sponsor for test interpretation and to publish. The urodynamic information collected using the study devices will be used in the UDS test interpretation for each subject enrolled, unless there is a reason to believe the test should be repeated (i.e. inconclusive results).",[53,54],"Lower Urinary Track Symptoms","Urodynamic Exam",[56,53],"Urodynamic","2026-04-23",{"date":59,"type":32},"2026-04-29",{"date":61,"type":32},"2025-08-15",{"date":63,"type":19},"2026-12",{"name":38,"class":39},1,""]